Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Quality Of Care Delivery In Colorectal Cancer Improved By Educational Initiatives
A study of targeted educational initiatives between the clinical staff at Fox Chase Cancer Center and the hospitals within their Partners program suggest that educational interventions by academic cancer centers can improve quality of care for cancer patients at community hospitals. The study, to be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology, looked specifically at the number of lymph nodes that were surgically removed in colorectal cancer patients at Fox Chase"s partner hospitals and the impact that educational initiatives by clinical staff had on improving the number of nodes removed.

How Consumers Continue Enjoying Their Favorite Experiences
We"ve all experienced listening to a song until we can"t stand it. A new study in the Journal of Consumer Research may help people continue to enjoy the products and experiences they once loved.
News of the day
'Shortcuts' Of The Mind Lead To Miscalculations Of Weight And Caloric Intake, Says Penn Study
Psychologists at the University of Pennsylvania have identified a cognitive shortcut, or heuristic, they call "Unit Bias," which causes people to ignore vital, obvious information in their decision-making process, points to a fundamental flaw in the modern, evolved mind and may also play a role in the American population"s 30 years of weight gain.
Diagnostics

Pharmalucence, Inc. Announces FDA Approval For Its Generic Sestamibi Kit

Pharmalucence, Inc., a leading supplier of radiopharmaceutical products, announced that it received approval from the U. S. Food and Drug Administration (FDA) Office of Generic Drugs for its Abbreviated New Drug Application (ANDA) to manufacture and market its Kit for the Preparation of Technetium Tc-99m Sestamibi Injection. The FDA has determined that Pharmalucence"s Sestamibi Kit is therapeutically equivalent to Cardiolite® 1, an imaging agent used in evaluating myocardial function and to detect coronary artery disease by localizing myocardial ischemia and infarction. The agent is also for use in breast imaging as a second line diagnostic after mammography to assist in the evaluation of breast lesions. Glenn Alto, President and CEO of Pharmalucence said, "When Pharmalucence was formed two years ago we committed to bring choice to the nuclear medicine community through an expanded line of radiopharmaceutical kits. The approval of our sestamibi kit marks the second generic imaging agent to emerge from the Pharmalucence Development team. Pharmalucence remains focused on delivering the products and enhancing the manufacturing assets that will provide nuclear medicine practitioners high quality imaging agents now and in the future." Pharmalucence will begin shipping their generic sestamibi kit on August 3. 1. Cardiolite® is a trademark of Lantheus Medical Imaging, Inc. Pharmalucence, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009